- Minaris and the Cell and Gene Therapy Catapult have announced a collaboration to develop viral vector delivery technologies aimed at improving manufacturing robustness, quality, and cost efficiency.
- As part of the agreement, Minaris will relocate its centre for viral vector innovation to CGT Catapult’s collaborator laboratories in London and jointly develop lentiviral and AAV capabilities.
Minaris has announced a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult) to develop delivery technologies for cell and gene therapies, with the aim of enabling more robust manufacturing processes, improved quality, and lower cost of goods. Minaris operates as a global cell and gene therapy CDMO and biosafety testing provider.
Under the collaboration, Minaris will move its centre for viral vector innovation into CGT Catapult’s collaborator laboratories in London. The two organisations will work together on the further development of lentiviral (LV) assays and processes, while CGT Catapult will expand its experience in the LV space through access to Minaris’ processes, expertise, and proprietary platforms.
The collaboration will also draw on CGT Catapult’s existing expertise in adeno-associated virus (AAV) technologies, with the aim of strengthening support for advanced therapy product developers and manufacturers that require LV and AAV platform capabilities. The partners said the expanded analytical and process development capabilities are intended to improve productivity, safety, and performance of viral vector platforms.
“Minaris’ expertise in cell and gene therapies is a valuable contribution to the UK’s advanced therapies industry. By working with Minaris to help refine the development and manufacture of lentivirus, we aim to ensure these processes are efficient, scalable, and safe for producing transformative therapies.”
Matthew Durdy, chief executive at the CGT Catapult
